ESCMID*  	ESCMID*  	 NNP	B-NP
guideline  	guideline  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 NN	O
and  	and  	 CC	O
management  	management  	 NN	O
of  	of  	 IN	O
Candida  	Candida  	 NNP	B-NP
diseases  	diseases  	 VBD	I-NP
2012 	2012 	 CD	O
:  	:  	 :	O
non-neutropenic  	non-neutropenic  	 JJ	B-NP
adult  	adult  	 NN	I-NP
patients  	patients  	 NNS	I-NP
This  	This  	 DT	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
EFISG  	EFISG  	 NNP	B-NP
guidelines  	guidelines  	 NNS	I-NP
focuses  	focuses  	 VBZ	O
on  	on  	 IN	O
non-neutropenic  	non-neutropenic  	 JJ	B-NP
adult  	adult  	 NN	I-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
Only  	Only  	 RB	O
a  	a  	 DT	O
few  	few  	 JJ	O
of  	of  	 IN	O
the  	the  	 DT	O
numerous  	numerous  	 JJ	B-NP
recommendations  	recommendations  	 NNS	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
summarized  	summarized  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
abstract 	abstract 	 NN	B-NP
.  	.  	 .	O
Prophylactic  	Prophylactic  	 JJ	B-NP
usage  	usage  	 NN	I-NP
of  	of  	 IN	I-NP
fluconazole  	fluconazole  	 NN	I-NP
is  	is  	 VBZ	O
supported  	supported  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
recent  	recent  	 JJ	O
abdominal  	abdominal  	 JJ	B-NP
surgery  	surgery  	 NN	I-NP
and  	and  	 CC	O
recurrent  	recurrent  	 JJ	O
gastrointestinal  	gastrointestinal  	 JJ	B-NP
perforations  	perforations  	 NN	I-NP
or  	or  	 CC	O
anastomotic  	anastomotic  	 JJ	B-NP
leakages 	leakages 	 NN	I-NP
.  	.  	 .	O
Candida  	Candida  	 JJ	B-NP
isolation  	isolation  	 NN	I-NP
from  	from  	 IN	O
respiratory  	respiratory  	 JJ	B-NP
secretions  	secretions  	 NNS	I-NP
alone  	alone  	 RB	O
should  	should  	 MD	O
never  	never  	 RB	O
prompt  	prompt  	 JJ	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
targeted  	targeted  	 JJ	O
initial  	initial  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
candidaemia 	candidaemia 	 NN	B-NP
,  	,  	 ,	O
echinocandins  	echinocandins  	 NNS	B-NP
are  	are  	 VBP	O
strongly  	strongly  	 RB	O
recommended  	recommended  	 VBN	O
while  	while  	 IN	O
liposomal  	liposomal  	 JJ	B-NP
amphotericin  	amphotericin  	 JJ	I-NP
B  	B  	 NNP	I-NP
and  	and  	 CC	O
voriconazole  	voriconazole  	 NNS	B-NP
are  	are  	 VBP	O
supported  	supported  	 VBN	O
with  	with  	 IN	O
moderate 	moderate 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
fluconazole  	fluconazole  	 NN	B-NP
with  	with  	 IN	O
marginal  	marginal  	 JJ	B-NP
strength 	strength 	 NN	I-NP
.  	.  	 .	O
Treatment  	Treatment  	 NN	B-NP
duration  	duration  	 NN	I-NP
for  	for  	 IN	I-NP
candidaemia  	candidaemia  	 NNS	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
a  	a  	 DT	O
minimum  	minimum  	 NN	O
of  	of  	 IN	O
14  	14  	 CD	O
days  	days  	 NNS	O
after  	after  	 IN	O
the  	the  	 DT	O
end  	end  	 NN	O
of  	of  	 IN	O
candidaemia 	candidaemia 	 NN	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
can  	can  	 MD	O
be  	be  	 VB	O
determined  	determined  	 VBN	O
by  	by  	 IN	O
one  	one  	 CD	O
blood  	blood  	 NN	O
culture  	culture  	 NN	O
per  	per  	 IN	O
day  	day  	 NN	O
until  	until  	 IN	O
negativity 	negativity 	 NN	B-NP
.  	.  	 .	O
Switching  	Switching  	 VBG	O
to  	to  	 TO	O
oral  	oral  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
after  	after  	 IN	O
10  	10  	 CD	O
days  	days  	 NNS	O
of  	of  	 IN	O
intravenous  	intravenous  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
safe  	safe  	 JJ	O
in  	in  	 IN	O
stable  	stable  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
susceptible  	susceptible  	 JJ	O
Candida  	Candida  	 JJ	B-NP
species 	species 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
candidaemia 	candidaemia 	 NN	B-NP
,  	,  	 ,	O
removal  	removal  	 NN	O
of  	of  	 IN	O
indwelling  	indwelling  	 JJ	O
catheters  	catheters  	 NN	B-NP
is  	is  	 VBZ	O
strongly  	strongly  	 RB	O
recommended 	recommended 	 VBN	O
.  	.  	 .	O
If  	If  	 IN	O
catheters  	catheters  	 NNS	B-NP
cannot  	cannot  	 RB	O
be  	be  	 VB	O
removed 	removed 	 VBN	O
,  	,  	 ,	O
lipid-based  	lipid-based  	 JJ	B-NP
amphotericin  	amphotericin  	 JJ	I-NP
B  	B  	 NNP	I-NP
or  	or  	 CC	O
echinocandins  	echinocandins  	 NNS	B-NP
should  	should  	 MD	O
be  	be  	 VB	O
preferred  	preferred  	 VBN	O
over  	over  	 IN	O
azoles 	azoles 	 NN	B-NP
.  	.  	 .	O
Transoesophageal  	Transoesophageal  	 JJ	B-NP
echocardiography  	echocardiography  	 NN	I-NP
and  	and  	 CC	O
fundoscopy  	fundoscopy  	 NNS	B-NP
should  	should  	 MD	O
be  	be  	 VB	O
performed  	performed  	 VBN	O
to  	to  	 TO	O
detect  	detect  	 VB	O
organ  	organ  	 JJ	B-NP
involvement 	involvement 	 NN	I-NP
.  	.  	 .	O
Native  	Native  	 JJ	B-NP
valve  	valve  	 JJ	I-NP
endocarditis  	endocarditis  	 NN	I-NP
requires  	requires  	 VBZ	O
surgery  	surgery  	 NN	O
within  	within  	 IN	O
a  	a  	 DT	O
week 	week 	 NN	B-NP
,  	,  	 ,	O
while  	while  	 IN	O
in  	in  	 IN	O
prosthetic  	prosthetic  	 JJ	B-NP
valve  	valve  	 JJ	I-NP
endocarditis 	endocarditis 	 NN	I-NP
,  	,  	 ,	O
earlier  	earlier  	 JJR	O
surgery  	surgery  	 NN	O
may  	may  	 MD	O
be  	be  	 VB	O
beneficial 	beneficial 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
antifungal  	antifungal  	 JJ	B-NP
regimen  	regimen  	 NN	I-NP
of  	of  	 IN	O
choice  	choice  	 NN	O
is  	is  	 VBZ	O
liposomal  	liposomal  	 JJ	B-NP
amphotericin  	amphotericin  	 JJ	I-NP
B  	B  	 NNP	I-NP
+ 	+ 	 NNP	O
/ 	/ 	 NNP	O
-  	-  	 :	O
flucytosine 	flucytosine 	 CD	O
.  	.  	 .	O
In  	In  	 IN	O
ocular  	ocular  	 JJ	B-NP
candidiasis 	candidiasis 	 NN	I-NP
,  	,  	 ,	O
liposomal  	liposomal  	 FW	B-NP
amphotericin  	amphotericin  	 FW	I-NP
B  	B  	 NNP	I-NP
+ 	+ 	 NNP	O
/ 	/ 	 NNP	O
-  	-  	 :	O
flucytosine  	flucytosine  	 NN	O
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
when  	when  	 WRB	O
the  	the  	 DT	O
susceptibility  	susceptibility  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
isolate  	isolate  	 NN	O
is  	is  	 VBZ	O
unknown 	unknown 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
in  	in  	 IN	O
susceptible  	susceptible  	 JJ	O
isolates 	isolates 	 NN	O
,  	,  	 ,	O
fluconazole  	fluconazole  	 NN	B-NP
and  	and  	 CC	O
voriconazole  	voriconazole  	 NNS	B-NP
are  	are  	 VBP	O
alternatives 	alternatives 	 NNS	O
.  	.  	 .	O
Amphotericin  	Amphotericin  	 NNP	B-NP
B  	B  	 NNP	I-NP
deoxycholate  	deoxycholate  	 NN	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
recommended  	recommended  	 VBN	O
for  	for  	 IN	O
any  	any  	 DT	O
indication  	indication  	 NN	O
due  	due  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
side  	side  	 NN	B-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
